Inclusive of all taxes
EMPARA FORTE TAB is a potent antidiabetic tablet combining Glimepiride 2 mg and Metformin Hydrochloride 1000 mg (Sustained Release) designed specifically for effective management of Type 2 Diabetes Mellitus (T2DM). This formulation is crafted under the Dr Precision label by BluepillExpress using WHO-GMP and ISO-certified pharmaceutical manufacturing standards, ensuring premium quality and precision in composition. The tablet leverages a dual mechanism of action: Glimepiride stimulates pancreatic beta-cell insulin secretion while Metformin (SR) reduces hepatic glucose production and enhances peripheral insulin sensitivity, delivering comprehensive glycemic control. EMPARA FORTE TAB is especially beneficial for T2DM patients who experience inadequate glucose control with monotherapy or require combination therapy per ADA/EASD guidelines. Suitable for bulk export, third-party manufacturing, and custom labeling, this formulation meets global regulatory and quality compliance with complete supporting documentation such as COA, MSDS, Stability Data, and CTD format dossiers. The sustained-release Metformin component allows for better patient compliance with minimized gastrointestinal side effects while ensuring stable blood glucose levels throughout the day. The product is optimized for international B2B markets demanding reliable, effective, and scalable antidiabetic solutions.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Glimepiride 2 mg and Metformin Hydrochloride 1000 mg (Sustained Release) |
| Therapeutic Use | Management of Type 2 Diabetes Mellitus (T2DM) |
| Mechanism of Action | Dual action: stimulates insulin secretion + decreases hepatic glucose production and enhances peripheral insulin sensitivity |
| Manufacturing Standards | WHO-GMP and ISO certified |
| Formulation Type | Sustained Release Tablet |
| Label & Branding | Dr Precision label by BluepillExpress |
| Regulatory Compliance | Complete regulatory documentation including COA, MSDS, Stability Data, CTD dossier |
| Target Market | Global markets for bulk export, third-party manufacturing, and custom labeling |
| Patient Suitability | T2DM patients inadequately controlled by monotherapy or with insulin resistance |
| Benefits | Synergistic glycemic control with reduced side effects and improved patient adherence |
| Attributes | Description |
|---|---|
| Dosage Form | Tablet |
| Dosage Strength | Glimepiride 2 mg + Metformin Hydrochloride 1000 mg SR |
| Pharmacological Class | Sulfonylurea + Biguanide |
| Indications | Type 2 Diabetes Mellitus with high fasting and postprandial glucose levels |
| Packaging | Available in bulk quantities for export/manufacturing |
| Storage | Store in a cool, dry place away from direct sunlight |
| Shelf Life | As per international pharmaceutical standards, typically 24 months |
| Manufacturing Location | BluepillExpress WHO-GMP and ISO-certified units |
| Compliance | GMP compliant, supports international regulatory registration |
| Route of Administration | Oral |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
EMPARA FORTE TAB contains sustained-release Metformin which allows for once or twice daily dosing with reduced gastrointestinal side effects, enhancing patient adherence over immediate-release formulations that often require multiple daily doses.
The combination targets two critical pathophysiological defects in Type 2 Diabetes — insulin secretion deficiency and insulin resistance — providing a synergistic effect for more effective blood glucose control than monotherapy alone.
Yes, EMPARA FORTE TAB is produced under stringent WHO-GMP and ISO standards, complete with international regulatory documentation, making it ideal for bulk export, institutional supply, and third-party labeling.
Yes, BluepillExpress offers custom labeling and packaging services for EMPARA FORTE TAB, supporting compliance with various international regulatory requirements.
EMPARA FORTE TAB uses fully validated stability protocols and comes with comprehensive documentation including Certificates of Analysis (COA), Material Safety Data Sheets (MSDS), Stability Data, and CTD format dossiers compliant with global regulations.
Country Of Origin: India
EMPARA FORTE TAB is a powerful combination of Glimepiride 2 mg and Metformin Hydrochloride 1000 mg (Sustained Release), used for the effective management of Type 2 Diabetes Mellitus (T2DM). It offers a dual mechanism to control blood glucose by stimulating insulin secretion and enhancing insulin sensitivity. Manufactured by BluepillExpress, this tablet is ideal for global markets seeking reliable antidiabetic formulations through bulk export, third-party manufacturing, or custom labeling.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
EMPARA FORTE TAB combines two clinically proven antidiabetic agents—Glimepiride, a sulfonylurea derivative, and Metformin Hydrochloride (Sustained Release), a biguanide—to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus. The synergistic action of these two drugs makes EMPARA FORTE TAB highly effective, especially in patients who require more than monotherapy to manage their blood glucose levels.
This formulation addresses both insulin resistance and beta-cell dysfunction, the two core pathophysiological defects in Type 2 diabetes. Glimepiride stimulates pancreatic beta cells to increase insulin secretion, while Metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Developed under the highest standards of pharmaceutical manufacturing at WHO-GMP and ISO-certified units of BluepillExpress, EMPARA FORTE TAB is suitable for third-party labeling, institutional supply, and international regulatory registrations. It is available in bulk quantities and supports full regulatory documentation (COA, MSDS, Stability Data, CTD Format Dossier).
✅ Therapeutic Indications
Type 2 Diabetes Mellitus (T2DM), when monotherapy is insufficient
Patients with high fasting and postprandial glucose levels
Diabetic patients with overweight or insulin resistance
Dual-drug therapy in progressive T2DM as per ADA/EASD guidelines
✅ Pharmacology and Mechanism of Action
Glimepiride:
Stimulates insulin release by closing ATP-sensitive potassium channels in pancreatic beta cells.
Enhances insulin receptor sensitivity in peripheral tissues.
Metformin (SR):
Decreases hepatic gluconeogenesis (glucose production).
Improves peripheral glucose uptake and utilization.
Reduces intestinal absorption of glucose.
Together, these agents offer fast onset (from Glimepiride) and sustained glucose control (from Metformin SR).
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
